Skip to content
lifestyle.smsolar.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
RenovoRx, Inc.
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
October 7, 2026
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform’s Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
October 1, 2026
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
September 2, 2026
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
August 25, 2026
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
August 21, 2026
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
August 20, 2026
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
August 12, 2026
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
August 11, 2026
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors
August 6, 2026
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th
August 4, 2026
1
2
3
Next Page
→